About this item:
1,400 Views | 1,912 Downloads
Author Notes:
Email Address:Wei Zhou:wzhou2@emory.edu
We would like to thank Dr. Anthea Hammond for editing this manuscript.
WZ is an Anise McDaniel Brock Scholar, a Georgia Cancer Coalition Distinguished Cancer, and an American Cancer Society Research Scholar.
Peer review under responsibility of Chongqing Medical University.
The authors declare no conflict of interest.
Subjects:
Research Funding:
This work was supported in part by R01-CA140571, P01 CA116676, Anise McDaniel Brock Scholar fund to WZ, 1R01CA142858 to AM, and P30CA138292 to Winship Cancer Institute.
Keywords:
- Cell polarity
- Oncogene
- RhoA
- Therapeutic target
- Tumor suppressor gene
RhoA, a novel tumor suppressor or oncogene as a therapeutic target?
Abstract:
Ras homolog gene family, member A (RhoA) is a small GTPase that plays critical roles in several essential cell functions, such as migration, adhesion, proliferation, and gene expression.1 RhoA switches between a GTP-bound active form and a GDP-bound inactive form. The activated RhoA directly interacts with its downstream effectors, such as Rho kinase (ROCK) to regulate actomyosin dynamics, or mDia1 to control stress fiber and filopodia formation. The activity of RhoA is primarily regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating protein (GAP), and guanine nucleotide-dissociation inhibitors (GDIs).
Copyright information:
© 2014, Chongqing Medical University
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License ( http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits distribution, public display, and publicly performance, making multiple copies, provided the original work is properly cited. This license requires copyright and license notices be kept intact, credit be given to copyright holder and/or author. This license prohibits exercising rights for commercial purposes.
